Nuclivision has raised a €5M seed round

We’re proud to announce the closing of our €5M seed round with HERAN Partners, LUMO Labs, and imec.istart future fund. Their trust, expertise, and capital will enable us to accelerate the commercialization of our PET image enhancement software, Nuclarity, across Europe and the US. This milestone also strengthens our commitment to continued innovation in the promising & growing field of nuclear medicine—driven by rising oncology volumes, radiotracer innovations, and the rise of theranostics. As one of the few software-first players, we’re uniquely positioned to make nuclear medicine safer, more affordable, and more accessible.

Nuclarity Clinical Study: cross-tracer, cross-center, multi-reader lesion detectability reader study

Following our latest whitepaper from 2024, we have now included 6 readers in our extended clinical study conducted as part of Nuclarity's clinical evaluation. The analyis holds promising results for Nuclarity in terms of image quality and lesion detectability accuracy.

Nuclivision featured in the news

Nuclivision was highlighted by Trends Kanaal Z as 'starter of the week', a category in their business magazine featuring promising startups.

Nuclivision attends EANM 2024 in Hamburg

Nuclivision will attend the 37th Annual EANM Congress to present research on PET image denoising and explore the latest innovations in AI, novel radiotracers, and theranostics, while connecting with industry leaders and startups.

Nuclarity Clinical Study: view our newest whitepaper

Clinical study conducted as part of Nuclarity's clinical evaluation.

Nuclivision achieves ISO 13485 certification

Nuclivision is now ISO 13485 certified, ensuring quality and safety in our medical imaging software development and operations.

Nuclivision joins wintercircus community

Selected out of 120 candidates, Nuclivision has secured a spot in the Ghent Wintercircus Community.

Best poster award AINM 2023

Nuclivision wins best poster award at the International Symposium on Artificial Intelligence in Nuclear Medicine in Groningen

Nuclivision has raised a €5M seed round

We’re proud to announce the closing of our €5M seed round with HERAN Partners, LUMO Labs, and imec.istart future fund. Their trust, expertise, and capital will enable us to accelerate the commercialization of our PET image enhancement software, Nuclarity, across Europe and the US. This milestone also strengthens our commitment to continued innovation in the promising & growing field of nuclear medicine—driven by rising oncology volumes, radiotracer innovations, and the rise of theranostics. As one of the few software-first players, we’re uniquely positioned to make nuclear medicine safer, more affordable, and more accessible.

Nuclivision featured in the news

Nuclivision was highlighted by Trends Kanaal Z as 'starter of the week', a category in their business magazine featuring promising startups.

Nuclivision attends EANM 2024 in Hamburg

Nuclivision will attend the 37th Annual EANM Congress to present research on PET image denoising and explore the latest innovations in AI, novel radiotracers, and theranostics, while connecting with industry leaders and startups.

Nuclivision achieves ISO 13485 certification

Nuclivision is now ISO 13485 certified, ensuring quality and safety in our medical imaging software development and operations.

Best poster award AINM 2023

Nuclivision wins best poster award at the International Symposium on Artificial Intelligence in Nuclear Medicine in Groningen

Nuclivision joins wintercircus community

Selected out of 120 candidates, Nuclivision has secured a spot in the Ghent Wintercircus Community.